# Xenetic Biosciences (XBIO) — News

XBIO · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/xbio/news

## Recent headlines

- [OFCOM: Decided to focus the remainder of investigation on X's compliance with its illegal content and complaints and reporting duties](https://www.ainvest.com/news/ofcom-decided-focus-remainder-investigation-compliance-illegal-content-complaints-reporting-duties-2610) — AInvest Wire, Oct 14, 2026
  The UK's communications regulator, Ofcom, has announced that it will focus the remainder of its investigation on X's compliance with its obligations regarding illegal content and complaints and reporting duties. This decision follows an ongoing review of the platform's adherence to the Online…
- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610-19) — AInvest Wire, Oct 13, 2026
  Cancer Prevention & Biotechnology Limited (CPBIO) has announced the renewal of its continuing connected transactions, as disclosed in a recent regulatory filing. The company has also issued a notice of a special general meeting (SGM) to be held on October 30, 2026, for shareholders to consider and…
- [CPBIO renewal of continuing connected transactions, notice of special general meeting](https://www.ainvest.com/news/cpbio-renewal-continuing-connected-transactions-notice-special-general-meeting-2610) — AInvest Wire, Oct 13, 2026
- [Xenetic Biosciences: Santersus shareholders to own about 85% of combined co post-closing - SEC filing](https://www.ainvest.com/news/xenetic-biosciences-santersus-shareholders-85-combined-post-closing-sec-filing-2609) — AInvest Wire, Sep 16, 2026
  According to a recent SEC filing, Santersus shareholders will hold approximately 85% of the combined company following the closing of the transaction with Xenetic Biosciences, Inc. Xenetic, a biopharmaceutical company focused on immuno-oncology technologies, is advancing its DNase technology to…
- [Xenetic Biosciences Inc: Deal expected to create Nasdaq-listed, multi-indication clinical-stage co](https://www.ainvest.com/news/xenetic-biosciences-deal-expected-create-nasdaq-listed-multi-indication-clinical-stage-2609) — AInvest Wire, Sep 16, 2026
  Xenetic Biosciences, Inc. (NASDAQ: XBIO) has taken significant steps toward becoming a Nasdaq-listed, multi-indication clinical-stage company. The firm transitioned from the OTCQB to the Nasdaq Capital Market on November 7, 2016, under the ticker symbol “XBIO”. This move was accompanied by a public…

---

Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).